SCHEMBL4539455

SCHEMBL4539455

NC(=O)C1CCNCC1.NC(=O)C1CCNCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.59
TSHR P16473 2/20 0.59
GABRG2 P18507 2/20 0.59
GABRB3 P28472 2/20 0.59
GABRA5 P31644 2/20 0.59
GABRA3 P34903 2/20 0.59
GABRA2 P47869 2/20 0.59
GABRA6 Q16445 2/20 0.59
GABRP O00591 1/20 0.59
GABRD O14764 1/20 0.59
GABRB1 P18505 1/20 0.59
GABRB2 P47870 1/20 0.59
GABRA4 P48169 1/20 0.59
GABRE P78334 1/20 0.59
PMP22 Q01453 1/20 0.59
GABRG1 Q8N1C3 1/20 0.59
GABRG3 Q99928 1/20 0.59
GABRQ Q9UN88 1/20 0.59
NOS2 P35228 1/20 0.56
KMT2A Q03164 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1298 1.00
Hydrochloric Acid SCHEMBL4716510 0.97 GABRA1 (0.56) GABRA1TSHRGABRG2GABRB3GABRA5
Hydrochloric Acid SCHEMBL2674808 0.97 GABRA1 (0.56) GABRA1TSHRGABRG2GABRB3GABRA5
Hydrochloric Acid SCHEMBL29868978 0.95 GABRA1 (0.54) GABRA1TSHRGABRG2GABRB3GABRA5
SCHEMBL4002484 0.91 KMT2A (0.69) GABRA1TSHRGABRG2GABRB3GABRA5
Benzene SCHEMBL16741898 0.91 GABRP (0.56) GABRA1TSHRGABRG2GABRB3GABRA5
Formic Acid SCHEMBL28944845 0.91 GABRA5 (0.50) GABRA1TSHRGABRG2GABRB3GABRA5
Acetic Acid SCHEMBL3154824 0.89 GABRP (0.54) GABRA1TSHRGABRG2GABRB3GABRA5
Methylene Chloride SCHEMBL27877964 0.89 GABRP (0.48) GABRA1TSHRGABRG2GABRB3GABRA5
Maleic Acid SCHEMBL4261390 0.87 TSHR (0.52) GABRA1TSHRGABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534889-B2 For reduced motility of gastrointestinal tract; irritable bowel syndrome (IBS), chronic constipation, dyspepsia, reflux disease; 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid ((1S,3R,5R)-8-{3-[(2-ethylsulfanylethyl)methanesulfonylamino]-2-hydroxypropyl}-8-aza-bicyclo[3.2.1]oct-3-yl)amide THERAVANCE, INC. (US) 2009-05-19 US disclosed
US-20080255187-A1 5-HT4 RECEPTOR AGONIST COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255187-A1 5-HT4 RECEPTOR AGONIST COMPOUNDS HTR4, HTR5A, HTR1A GABRA1 524/4885TSHR 214/4885GABRG2 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.